AptaBio Therapeutics Inc.
Financials
Valuation Metrics
AptaBio Therapeutics Inc.'s Market Cap is ₩1551B. At end of 2025 it was ₩2627B. Ranked #998 of 2,436 in KR market (top 41%), #491 of 1,649 on KOSDAQ (top 30%), #118 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 50%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 155.08B KRW | KR#998/2,436 Sec#118/234 |
| Revenue | 4.27B KRW | KR#2,356/2,436 Sec#201/234 |
| Net Income | -20.21B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 53.75B KRW | KR#2,158/2,436 Sec#193/234 |
| Net Assets | 40.89B KRW | KR#2,011/2,436 Sec#176/234 |
| Employees | 34 | KR#2,153/2,436 Sec#197/234 |
| Value | ||
| P/B | 3.79x | KR#2,179/2,436 Sec#178/234 |
| P/S | 36.30x | KR#2,357/2,436 Sec#193/234 |
| Profitability | ||
| ROE | -49.42% | KR#2,268/2,436 Sec#199/234 |
| ROA | -37.60% | KR#2,336/2,436 Sec#214/234 |
| Op. Margin | -451.87% | KR#2,374/2,436 Sec#208/234 |
| Revenue Growth | 150.17% | KR#92/2,436 Sec#16/234 |
| Financial Health | ||
| Debt Ratio | 131.43% | KR#883/2,436 Sec#102/234 |
| Total Debt | 12.28B KRW | KR#1,546/2,436 Sec#140/234 |
| Cash | 7.82B KRW | KR#1,806/2,436 Sec#156/234 |
| Current Ratio | 1.72x | KR#1,134/2,436 Sec#122/234 |
| Performance | ||
| 1Y Return | -32.93% | KR#1,746/2,436 Sec#153/234 |
| 1M Return | 22.12% | KR#172/2,436 Sec#13/234 |
| From 52W High | -49.31% | KR#1,280/2,436 Sec#110/234 |
| 1Y MDD | -61.69% | KR#1,504/2,436 Sec#118/234 |
| Trading | ||
| Volume | 81,090 shares | KR#696/2,436 Sec#67/234 |
| Foreign Own. | 2.75% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | -743 KRW | KR—/2,436 Sec—/234 |
| BPS | 1,456 KRW | KR#2,172/2,436 Sec#190/234 |
Company Info
Aptabio, established in 2009 and specially listed on KOSDAQ in 2019, is a new drug development company based on platform technology, headquartered in Yongin-si, Gyeonggi-do. The company develops innovative new drugs, including for diabetes complications and as immune-oncology agents, utilizing three platform technologies: oxidative stress regulation, CAF modulation, and aptamer-drug conjugates. Aptabio launched health functional food Original Design Manufacturer (ODM) and pet care businesses in 2023, plans to merge Objectivo in 2025, and has successfully achieved three technology transfers with its proprietary technologies.